Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety and intraoperative imaging study of VB5-845D-800CW in gastrointestinal cancer
NL-OMON48830Phase 1Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of VB5-845D-800CW in esophageal cancer, gastric cancer (GC) and colorectal cancer (CRC) (6 arms), sponsored by Leiden University Medical Center. Primary endpoints: Treatment-emergent adverse events, Concomitant medication and 4 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
VB5-845D-800CW
03
Conditions
esophageal cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON48830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48830.